A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicity

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 5, 2011, Pages 1145-1155

  Patel, Kashyap ^a   Choy, Steve S F ^b   Hicks, Kevin O ^a   Melink, Teresa J ^c   Holford, Nicholas H G ^b   Wilson, William R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c Proacta Inc   (United States)

Author keywords

Allometry; Hypoxia activated prodrugs; Nitrogen mustards; Pharmacokinetics; PR 104

Indexed keywords

ANTINEOPLASTIC AGENT; PR 104; PR 104A; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BOLUS INJECTION; BONE MARROW TOXICITY; COMPARTMENT MODEL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; EXPERIMENTAL DOG; FEMALE; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SOLID TUMOR; SPECIES DIFFERENCE; SPRAGUE DAWLEY RAT; STEADY STATE;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD PROTEINS; CELL HYPOXIA; CLINICAL TRIALS, PHASE I AS TOPIC; DOGS; FEMALE; HUMANS; MALE; MICE; MICE, NUDE; MODELS, BIOLOGICAL; NITROGEN MUSTARD COMPOUNDS; PRODRUGS; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY;

EID: 79955569633     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1412-z     Document Type: Article

References (39)

1. P Carmeliet 2005 Angiogenesis in life, disease and medicine Nature 438 932 936 16355210 10.1038/nature04478 1:CAS:528:DC%2BD2MXhtlSksrjF (Pubitemid 43093958)
2. D Liao RS Johnson 2007 Hypoxia: a key regulator of angiogenesis in cancer Cancer Metastasis Rev 26 281 290 17603752 10.1007/s10555-007-9066-y 1:CAS:528:DC%2BD2sXotFWrtLw%3D (Pubitemid 47101669)
3. M Kioi H Vogel G Schultz RM Hoffman GR Harsh JM Brown 2010 Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice J Clin Invest 120 694 705 20179352 10.1172/JCI40283 1:CAS:528:DC%2BC3cXjtV2ns74%3D
4. JT Erler AJ Giaccia 2006 Lysyl oxidase mediates hypoxic control of metastasis Cancer Res 66 10238 10241 17079439 10.1158/0008-5472.CAN-06-3197 1:CAS:528:DC%2BD28XhtFGjsrvM (Pubitemid 44799737)
5. JL O'Donnell MR Joyce AM Shannon J Harmey J Geraghty D Bouchier-Hayes 2006 Oncological implications of hypoxia inducible factor-1alpha (HIF-1alpha) expression Cancer Treat Rev 32 407 416 16889900 10.1016/j.ctrv.2006.05.003 (Pubitemid 44309247)
6. RG Bristow RP Hill 2008 Hypoxia, DNA repair and genetic instability Nat Rev Cancer 8 180 192 18273037 10.1038/nrc2344 1:CAS:528:DC%2BD1cXitlOisrw%3D (Pubitemid 351301853)
7. RA Gatenby RJ Gillies 2007 Glycolysis in cancer: a potential target for therapy Int J Biochem Cell Bio 39 1358 1366 10.1016/j.biocel.2007.03.021 1:CAS:528:DC%2BD2sXnslWltLg%3D (Pubitemid 47031043)
8. AC Koong V Chauhan L Romero-Ramirez 2006 Targeting XBP-1 as a novel anti-cancer strategy Cancer Biol Ther 5 756 759 16861911 10.4161/cbt.5.7.2973 1:CAS:528:DC%2BD28XhtVOju77L (Pubitemid 44775129)
9. TG Graeber C Osmanian T Jacks DE Housman CJ Koch SW Lowe AJ Giaccia 1996 Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours Nature 379 88 91 8538748 10.1038/379088a0 1:CAS:528: DyaK28XivVKgug%3D%3D (Pubitemid 26008141)
10. JM Brown WR Wilson 2004 Exploiting tumor hypoxia in cancer treatment Nat Rev Cancer 4 437 447 15170446 10.1038/nrc1367 1:CAS:528:DC%2BD2cXksVaisbs%3D (Pubitemid 38745529)
11. JL Tatum GJ Kelloff RJ Gillies JM Arbeit JM Brown KS Chao JD Chapman WC Eckelman AW Fyles AJ Giaccia RP Hill CJ Koch MC Krishna KA Krohn JS Lewis RP Mason G Melillo AR Padhani G Powis JG Rajendran R Reba SP Robinson GL Semenza HM Swartz P Vaupel D Yang B Croft J Hoffman G Liu H Stone D Sullivan 2006 Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy Int J Radiat Biol 82 699 757 17118889 10.1080/09553000601002324 1:CAS:528:DC%2BD28XhtlejsbnM (Pubitemid 44832019)
12. IJ Stratford P Workman 1998 Bioreductive drugs into the next millennium Anticancer Drug Des 13 519 528 9755716 1:CAS:528:DyaK1cXmt1aksrw%3D (Pubitemid 28410146)
13. WA Denny 2001 Prodrug strategies in cancer therapy Eur J Med Chem 36 577 595 11600229 10.1016/S0223-5234(01)01253-3 1:CAS:528:DC%2BD3MXnsVKksbg%3D (Pubitemid 32964730)
14. P Wardman 2001 Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia Curr Med Chem 8 739 761 11375747 1:CAS:528:DC%2BD3MXjsVChtbg%3D (Pubitemid 32427904)
15. SR McKeown RL Cowen KJ Williams 2007 Bioreductive drugs: from concept to clinic Clin Oncol 19 427 442 10.1016/j.clon.2007.03.006 1:STN:280: DC%2BD2szpsVSkug%3D%3D (Pubitemid 46995614)
16. Y Chen L Hu 2009 Design of anticancer prodrugs for reductive activation Med Res Rev 29 29 64 18688784 10.1002/med.20137
17. MB Jameson D Rischin M Pegram J Gutheil AV Patterson WA Denny WR Wilson 2010 A phase I pharmacokinetic trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors Cancer Chemother Pharmacol 65 791 801 20012293 10.1007/s00280-009-1188-1 1:CAS:528:DC%2BC3cXotVGlsQ%3D%3D
18. AV Patterson DM Ferry SJ Edmunds Y Gu RS Singleton K Patel SM Pullen SP Syddall GJ Atwell S Yang WA Denny WR Wilson 2007 Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA crosslinking agent PR-104 Clin Cancer Res 13 3922 3932 17606726 10.1158/1078-0432.CCR-07-0478 1:CAS:528:DC%2BD2sXntFymt7w%3D (Pubitemid 47037600)
19. RS Singleton CP Guise DM Ferry SM Pullen MJ Dorie JM Brown AV Patterson WR Wilson 2009 DNA crosslinks in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism and cytotoxicity Cancer Res 69 3884 3891 19366798 10.1158/0008-5472.CAN-08-4023 1:CAS:528:DC%2BD1MXltFOksLg%3D
20. CP Guise A Wang A Thiel D Bridewell WR Wilson AV Patterson 2007 Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia Biochem Pharmacol 74 810 820 17645874 10.1016/j.bcp.2007.06.014 1:CAS:528:DC%2BD2sXovFOjtrk%3D (Pubitemid 47212075)
21. CP Guise M Abbattista RS Singleton SD Holford J Connolly GU Dachs SB Fox R Pollock J Harvey P Guilford F Doñate WR Wilson AV Patterson 2010 The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3 Cancer Res 70 1573 1584 20145130 10.1158/0008-5472.CAN- 09-3237 1:CAS:528:DC%2BC3cXhvFaksbg%3D
22. KO Hicks H Myint AV Patterson FB Pruijn BG Siim K Patel WR Wilson 2007 Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine Int J Radiat Oncol Biol Phys 69 560 571 17869669 10.1016/j.ijrobp.2007.05.049 1:CAS:528:DC%2BD2sXhtVeqs7jI (Pubitemid 47380109)
23. WR Wilson KO Hicks SM Pullen DM Ferry NA Helsby AV Patterson 2007 Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards Radiat Res 167 625 636 17523848 10.1667/RR0807.1 1:CAS:528:DC%2BD2sXmtFKjtLg%3D (Pubitemid 351292942)
24. SC Liu GO Ahn M Kioi MJ Dorie AV Patterson JM Brown 2008 Optimised Clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA crosslinking agent PR-104 Cancer Res 68 7995 8003 18829557 10.1158/0008-5472.CAN-08-1698 1:CAS:528:DC%2BD1cXhtF2msLrP
25. K Patel D Lewiston Y Gu KO Hicks WR Wilson 2007 Analysis of the hypoxia-activated dinitrobenzamide mustard phosphate prodrug PR-104 and its alcohol metabolite PR-104A in plasma and tissues by liquid chromatography-mass spectrometry J Chromatogr B Analyt Technol Biomed Life Sci 856 302 311 17644498 10.1016/j.jchromb.2007.06.035 1:CAS:528:DC%2BD2sXpvFKgur8%3D (Pubitemid 47302931)
26. Y Gu WR Wilson 2009 Rapid and sensitive ultra-high-pressure liquid chromatography-tandem mass spectrometry analysis of the novel anticancer agent PR-104 and its major metabolites in human plasma: application to a pharmacokinetic study J Chromatogr B Analyt Technol Biomed Life Sci 877 3181 3186 19709934 10.1016/j.jchromb.2009.08.009 1:CAS:528:DC%2BD1MXhtFams7nO
27. Jameson MB, McKeage MJ, Ramanathan RK, Rajendran J, Gu Y, Wilson WR, Melink TJ, Tchekmedyian NS (2010) Final results of a phase Ib trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, in combination with gemcitabine or docetaxel in patients with advanced solid tumors. ASCO Meeting Abstracts (Abstract 2554)
28. BJ Anderson NHG Holford 2008 Mechanism-based concepts of size and maturity in pharmacokinetics Ann Rev Pharmacol Toxicol 48 303 332 10.1146/annurev.pharmtox.48.113006.094708 1:CAS:528:DC%2BD1cXisFynu7g%3D (Pubitemid 351738156)
29. Denny WA, Atwell GJ, Yang S, Wilson WR, Patterson AV, Helsby NA (2005) Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents. PCT WO2005042471A1
30. NHG Holford 1996 A size standard for pharmacokinetics Clin Pharmacokinet 30 329 332 8743333 10.2165/00003088-199630050-00001 1:STN:280: DyaK28zjtVKluw%3D%3D (Pubitemid 26177179)
31. GB West JH Brown BJ Enquist 1997 A general model for the origin of allometric scaling laws in biology Science 279 122 126 10.1126/science.276.5309. 122 (Pubitemid 27161259)
32. GB West JH Brown BJ Enquist 1999 The fourth dimension of life: fractal geometry and allometric scaling of organisms Science 284 1677 1679 10356399 10.1126/science.284.5420.1677 1:CAS:528:DyaK1MXjs1Kitbo%3D (Pubitemid 29291379)
33. BJ Anderson GA Woollard NHG Holford 2000 A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children Br J Clin Pharmacol 502 125 134 10.1046/j.1365-2125.2000.00231.x (Pubitemid 30612030)
34. T Kolokotrones V Savage EJ Deeds W Fontana 2010 Curvature in metabolic scaling Nature 464 753 756 20360740 10.1038/nature08920 1:CAS:528: DC%2BC3cXktVygsbc%3D
35. Y Gu GJ Atwell WR Wilson 2010 Metabolism and excretion of the novel bioreductive prodrug PR-104 in mice, rats, dogs and humans Drug Metab Dispos 38 498 508 20019245 10.1124/dmd.109.030973 1:CAS:528:DC%2BC3cXjt1OrtLo%3D
36. Y Gu CP Guise K Patel MR Abbattista J Lie X Sun GJ Atwell M Boyd AV Patterson WR Wilson 2010 Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice Cancer Chemother Pharmacol 10.1007/s00280-010-1354-5
37. P Velica NJ Davies PP Rocha H Schrewe JP Ride CM Bunce 2009 Lack of functional and expression homology between human and mouse aldo-keto reductase 1C enzymes: implications for modelling human cancers Mol Cancer 8 121 132 20003443 10.1186/1476-4598-8-121
38. J Birtwistle RE Hayden FL Khanim RM Green C Pearce NJ Davies N Wake H Schrewe JP Ride JK Chipman CM Bunce 2009 The aldo-keto reductase AKR1C3 contributes to 7, 12-dimethylbenz(a)anthracene-3, 4-dihydrodiol mediated oxidative DNA damage in myeloid cells: implications for leukemogenesis Mutat Res 662 67 74 19162045 1:CAS:528:DC%2BD1MXisFWqu7o%3D
39. JK Peterson PJ Houghton 2004 Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development Eur J Cancer 40 837 844 15120039 10.1016/j.ejca.2004.01.003 1:CAS:528:DC%2BD2cXivVCksL8%3D (Pubitemid 38519762)